Identifying High-Risk Smoldering Multiple Myeloma for Early Intervention

JAMA Oncology · Published 2026-04-23 · DOI 10.1001/jamaoncol.2026.0831

Free full text

Authors being retrieved — see the publisher record. https://doi.org/10.1001/jamaoncol.2026.0831

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Related articles

• Not all methods for identifying high‐risk smoldering myeloma measure up · Cancer · 2026 · Cites or is cited by this article
• Daratumumab and hyaluronidase-fihj, a monotherapy for high-risk smoldering multiple myeloma: a shift in preventing active myeloma? · Expert Review of Hematology · 2026 · Cites or is cited by this article
• Considerations in Genomic Therapy Matching—Reply · JAMA Oncology · 2026 · Same journal
• Survival Language · JAMA Oncology · 2026 · Same journal
• Global Consensus on the Management of Primary Localized Chordoma · JAMA Oncology · 2026 · Same journal
• Survival in the SONIA Trial—Reply · JAMA Oncology · 2026 · Same journal
• When TNM Staging Is Not Sufficient · JAMA Oncology · 2026 · Same journal
• Transarterial Chemoembolization Plus Thermal Ablation in Unresectable Hepatocellular Carcinoma · JAMA Oncology · 2026 · Same journal
• Treatment Delays in Early Age–Onset Colorectal Cancer · JAMA Oncology · 2026 · Same journal
• Fluids for Immune Checkpoint Inhibitor Diabetic Ketoacidosis—Reply · JAMA Oncology · 2026 · Same journal